
|Videos|August 25, 2017
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
Author(s)Prudence A. Francis, MD
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer.
Advertisement
In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal estrogen receptor (ER)-positive breast cancer.
Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
4
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
5





















































